MX9707674A - Uso de una linfosina que suprime el virus de inmunodeficiencia (isl) para inhibir la replicacion de los virus, en particular de los retrovirus. - Google Patents

Uso de una linfosina que suprime el virus de inmunodeficiencia (isl) para inhibir la replicacion de los virus, en particular de los retrovirus.

Info

Publication number
MX9707674A
MX9707674A MX9707674A MX9707674A MX9707674A MX 9707674 A MX9707674 A MX 9707674A MX 9707674 A MX9707674 A MX 9707674A MX 9707674 A MX9707674 A MX 9707674A MX 9707674 A MX9707674 A MX 9707674A
Authority
MX
Mexico
Prior art keywords
retroviruses
replication
coded
seq
isl
Prior art date
Application number
MX9707674A
Other languages
English (en)
Other versions
MXPA97007674A (es
Inventor
Reinhard Kurth
Michael Baier
Karin Metzner
Albrecht Werner
Original Assignee
Republica Fed De Alemania
Representada Por El Ministro F
Para La Salud L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Republica Fed De Alemania, Representada Por El Ministro F, Para La Salud L filed Critical Republica Fed De Alemania
Publication of MX9707674A publication Critical patent/MX9707674A/es
Publication of MXPA97007674A publication Critical patent/MXPA97007674A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5446—IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/141—Interleukin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Un polipéptido aislado que inhibe la replicacion de los retrovirus en los linfocitos sanguíneos periféricos y i) se codifica por la secuencia de ADN mostrada en SEQ ID No: 1 o secuencias complementarias; ii) se codifica por las secuencias de ADN que se hibridizan con SEA ID No: 1 o SEQ ID No: 3 bajo condiciones severas; iii) se codifica por las secuencias de ADN, que, si no hay degeneracion del codigo genético, se hibridizarán bajo condiciones severas con las secuencias definidas en i) a ii); es util como un agente terapéutico para el tratamiento en infecciones virales y enfermedades de proliferacion benignas y malignas.
MXPA/A/1997/007674A 1995-04-07 1997-10-06 Uso de una linfosina que suprime el virus de inmunodeficiencia (isl) para inhibir la replicacion de los virus, en particular de los retrovirus MXPA97007674A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19513152A DE19513152A1 (de) 1995-04-07 1995-04-07 Verwendung eines "Immundefizienzvirus-supprimierenden Lymphokins (ISL)" zur Hemmung der Virusvermehrung, insbesondere von Retroviren
DE19513152.5 1995-04-07
EP95113013A EP0736600A3 (en) 1995-04-07 1995-08-18 Use of an immunodeficiency suppressing virus which suppresses lymphokines (ISL) to prevent viral replicas, in particular those of retroviruses
EP95113013 1995-08-18

Publications (2)

Publication Number Publication Date
MX9707674A true MX9707674A (es) 1998-08-30
MXPA97007674A MXPA97007674A (es) 1998-11-12

Family

ID=

Also Published As

Publication number Publication date
KR19980703704A (ko) 1998-12-05
EP0736600A2 (en) 1996-10-09
WO1996031607A2 (en) 1996-10-10
EP0821734A2 (en) 1998-02-04
DE19513152A1 (de) 1996-10-10
AU5686196A (en) 1996-10-23
JPH10507369A (ja) 1998-07-21
CA2217450A1 (en) 1996-10-10
EP0736600A3 (en) 1997-01-02
US5985613A (en) 1999-11-16
WO1996031607A3 (en) 1996-12-27
US6383739B1 (en) 2002-05-07
AU712852B2 (en) 1999-11-18
NZ307494A (en) 1999-02-25
KR100262420B1 (ko) 2000-08-01

Similar Documents

Publication Publication Date Title
WO1996031607A3 (en) Use of an 'immunodeficiency-virus suppressing lymphokine (isl)' to inhibit the replication of viruses, in particular of retroviruses
CA2308116A1 (en) Low-toxicity human interferon-alpha analog
NZ302984A (en) Multifunctional enzyme having N-terminal sequence IVGGXEVTPHAYPWQVGLFIDDMYF, where X is any amino acid
CA2165821A1 (en) Antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection
ATE319827T1 (de) Polypeptid, das die differenzierung unterdrueckt
AUPO784197A0 (en) Treatment of nasopharyngeal carcinoma
DE69528751T2 (de) Verwendung von Interferon-alpha 8 subtype zur Herstellung von Medikamenten zur Behandlung von Viralinfektionen der Leber
IL161591A (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
PL340755A1 (en) Polypeptide-10 similar to mammal cytokin
DK0662157T3 (da) Præparater og fremgangsmåde til behandling af Hepatitis C-virus-associerede sygdomme
EP0301570A3 (en) Oligopeptides useful for treating aids
EP0625991A4 (en) IMPROVED ALPHA INTERFERON COMPOSITION AND METHOD FOR THE PRODUCTION THEREOF FROM LEUKOCYTES OF THE HUMAN PERIPHERAL BLOOD.
AU5110490A (en) Immunogenic regions on the e7 protein of human papillomavirus type 16
AU2002307510A1 (en) Cytokine protein family
GB9310657D0 (en) Retrovirus
AP1674A (en) The genome of the HIV-1 inter-subtype (C/B') and use thereof.
WO1999009054A3 (en) Peroxisome-associated polypeptide, nucleotide sequence encoding said polypeptide and their uses in the diagnosis and/or the treatment of lung injuries and diseases, and of oxidative stress-related disorders
AR005750A1 (es) Composicion farmaceutica para tratar o prevenir infecciones con zoster en personas infectadas con el virus de varicela zoster y procedimiento para preparar dicha composicion
ATE296314T1 (de) Peptide des env-gens vom katze immunschwäche- virus und deren verwendung
AU4312093A (en) Use of a hymenoptera venom for the manufacture of a medicament for treating dna virus infections
CA2383850A1 (en) Prevention and treatment of mycoplasma-associated diseases
ES2138565A1 (es) Uso del interferon alfa 5 en el tratamiento de las haepatopatias virales.
NZ256246A (en) Serine leukocyte protease inhibitor, recombinant preparation thereof, and treatment of a retroviral infection
NZ505350A (en) DNA encoding a tumour antigen peptide (43 kDa) for diagnosis or treatment of tumours
GB9106278D0 (en) Method of treatment

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees